NBRV
$0.45
Nabriva Therape Ads
$.02
4.63%
NBRV
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($0.09)
Revenue:  $0.61 Mil
Thursday
Feb 4
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when NBRV reports earnings?
Beat
Meet
Miss

Where is NBRV's stock price going from here?
Up
Flat
Down
Stock chart of NBRV
Analysts
Summary of analysts' recommendations for NBRV
Score
Grade
Pivots
Resistance
$0.51
$0.49
$0.47

$0.45

Support
$0.43
$0.41
$0.39
Tweet
Growth
Description
Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP).